115 Publications (Page 2 of 5)
2016
Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)Weber, Jeffrey S⋅Gibney, Geoffrey Thomas⋅Sullivan, Ryan J⋅Sosman, Jeffrey Alan⋅Slingluff, Craig L⋅Lawrence, Donald P⋅Logan, Theodore F⋅Schuchter, Lynn Mara⋅Nair, Suresh⋅Buchbinder, Elizabeth Iannotti⋅Berghorn, Elmer⋅Jiang, Joel⋅Horak, Christine E and Hodi, F. StephenJournal of Clinical Oncology, vol. 34, (no. 15_suppl), pp. 9517, 2016-05-20.
| Journal Article
2015
Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.Bradish, Joshua R⋅Bradish, Joshua R⋅Bradish, Joshua R⋅Richey, Justin D⋅Richey, Justin D⋅Richey, Justin D⋅Post, Kristin M⋅Post, Kristin M⋅Post, Kristin M⋅Meehan, Kari⋅Meehan, Kari⋅Meehan, Kari⋅Sen, Joyashree D⋅Sen, Joyashree D⋅Sen, Joyashree D⋅Malek, Amanda J⋅Malek, Amanda J⋅Malek, Amanda J⋅Katona, Terrence M⋅Katona, Terrence M⋅Katona, Terrence M⋅Warren, Simon⋅Warren, Simon⋅Warren, Simon⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Fecher, Leslie A⋅Fecher, Leslie A⋅Fecher, Leslie A⋅Cheng, Liang⋅Cheng, Liang and Cheng, LiangModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, vol. 28, (no. 4), pp. 480-486, April 2015.
| Journal Article
Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN)Armstrong, Andrew J⋅Broderick, Samuel⋅Eisen, Tim⋅Stadler, Walter Michael⋅Jones, Robert J⋅Garcia, Jorge A⋅Vaishampayan, Ulka N⋅Picus, Joel⋅Hawkins, Robert E⋅Hainsworth, John D⋅Kollmannsberger, Christian K⋅Logan, Theodore F⋅Puzanov, Igor⋅Pickering, Lisa M⋅Ryan, Christopher W⋅Protheroe, Andrew⋅Lusk, Christine M⋅Oberg, Sadie⋅Halabi, Susan and George, Daniel JJournal of Clinical Oncology, vol. 33, (no. 15_suppl), pp. 4507, 2015-05-20.
| Journal Article
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.Motzer, Robert J⋅Rini, Brian I⋅Mc Dermott, David F⋅Redman, Bruce G⋅Kuzel, Timothy M⋅Harrison, Michael R⋅Vaishampayan, Ulka N⋅Drabkin, Harry A⋅George, Saby⋅Logan, Theodore F⋅Margolin, Kim A⋅Plimack, Elizabeth R⋅Lambert, Alexandre M⋅Waxman, Ian M and Hammers, Hans JJournal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 33, (no. 13), pp. 1430-1437, May 1, 2015.
| Journal Article
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.Amin, Asim⋅Dudek, Arkadiusz Z⋅Logan, Theodore F⋅Lance, Raymond S⋅Holzbeierlein, Jeffrey M⋅Knox, Jennifer J⋅Master, Viraj A⋅Pal, Sumanta K⋅Miller, Wilson H⋅Karsh, Lawrence I⋅Tcherepanova, Irina Y⋅DeBenedette, Mark A⋅Williams, W Lee⋅Plessinger, Douglas C⋅Nicolette, Charles A and Figlin, Robert AJournal for immunotherapy of cancer, vol. 3, pp. 14, 2015.
| Journal Article
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.Mc Dermott, David F⋅McDermott, David F⋅Cheng, Su-Chun⋅Cheng, Su-Chun⋅Signoretti, Sabina⋅Signoretti, Sabina⋅Margolin, Kim A⋅Margolin, Kim A⋅Clark, Joseph I⋅Clark, Joseph I⋅Sosman, Jeffrey A⋅Sosman, Jeffrey A⋅Dutcher, Janice P⋅Dutcher, Janice P⋅Logan, Theodore F⋅Logan, Theodore F⋅Curti, Brendan D⋅Curti, Brendan D⋅Ernstoff, Marc S⋅Ernstoff, Marc S⋅Appleman, Leonard⋅Appleman, Leonard⋅Wong, Michael K K⋅Wong, Michael K K⋅Khushalani, Nikhil I⋅Khushalani, Nikhil I⋅Oleksowicz, Leslie⋅Oleksowicz, Leslie⋅Vaishampayan, Ulka N⋅Vaishampayan, Ulka N⋅Mier, James W⋅Mier, James W⋅Panka, David J⋅Panka, David J⋅Bhatt, Rupal S⋅Bhatt, Rupal S⋅Bailey, Alexandra S⋅Bailey, Alexandra S⋅Leibovich, Bradley C⋅Leibovich, Bradley C⋅Kwon, Eugene D⋅Kwon, Eugene D⋅Kabbinavar, Fairooz F⋅Kabbinavar, Fairooz F⋅Belldegrun, Arie S⋅Belldegrun, Arie S⋅Figlin, Robert A⋅Figlin, Robert A⋅Pantuck, Allan J⋅Pantuck, Allan J⋅Regan, Meredith M⋅Regan, Meredith M⋅Atkins, Michael B and Atkins, Michael BClinical cancer research : an official journal of the American Association for Cancer Research, vol. 21, (no. 3), pp. 561-568, February 1, 2015.
| Journal Article
Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC)Plimack, Elizabeth R⋅Hammers, Hans J⋅Rini, Brian I⋅McDermott, David F⋅Redman, Bruce⋅Kuzel, Timothy⋅Harrison, Michael Roger⋅Vaishampayan, Ulka N⋅Drabkin, Harry A⋅George, Saby⋅Logan, Theodore F⋅Margolin, Kim Allyson⋅Xu, Li-an⋅Waxman, Ian and Motzer, RobertJournal of Clinical Oncology, vol. 33, (no. 15_suppl), pp. 4553, 2015-05-20.
| Journal Article
Whole-body PET/CT evaluation of tumor perfusion using generator-based 62Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II): validation by direct comparison to 15O-water in metastatic renal cell carcinoma.Fletcher, James W⋅Fletcher, James W⋅Logan, Theodore F⋅Logan, Theodore F⋅Eitel, Jacob A⋅Eitel, Jacob A⋅Mathias, Carla J⋅Mathias, Carla J⋅Ng, Yen⋅Ng, Yen⋅Lacy, Jeffrey L⋅Lacy, Jeffrey L⋅Hutchins, Gary D⋅Hutchins, Gary D⋅Green, Mark A and Green, Mark AJournal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 56, (no. 1), pp. 56-62, January 2015.
| Journal Article
2014
A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)Clark, Joseph⋅Clark, Joseph⋅Flaherty, Lawrence⋅Flaherty, Lawrence⋅Ernstoff, Marc⋅Ernstoff, Marc⋅Koon, Henry⋅Koon, Henry⋅Milhem, Mohammed⋅Milhem, Mohammed⋅Militello, Gerald⋅Militello, Gerald⋅Agarwala, Sanjiv⋅Agarwala, Sanjiv⋅Curti, Brendan⋅Curti, Brendan⋅Cranmer, Lee⋅Cranmer, Lee⋅Lao, Christopher D⋅Lao, Christopher D⋅Logan, Theodore F⋅Logan, Theodore F⋅Lutzky, Jose⋅Lutzky, Jose⋅Rudrapatna, Venkatesh⋅Rudrapatna, Venkatesh⋅Daniels, Gregory⋅Daniels, Gregory⋅Taback, Bret⋅Taback, Bret⋅Aung, Sandra⋅Aung, Sandra⋅Lowder, James⋅Lowder, James⋅Lawson, David and Lawson, DavidJournal for ImmunoTherapy of Cancer, vol. 2, (no. Suppl 3), pp. P77, 2014-00-00.
| Journal Article
A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)Clark, Joseph⋅Clark, Joseph⋅Flaherty, Lawrence⋅Flaherty, Lawrence⋅Ernstoff, Marc⋅Ernstoff, Marc⋅Koon, Henry⋅Koon, Henry⋅Milhem, Mohammed⋅Milhem, Mohammed⋅Militello, Gerald⋅Militello, Gerald⋅Agarwala, Sanjiv⋅Agarwala, Sanjiv⋅Curti, Brendan⋅Curti, Brendan⋅Cranmer, Lee⋅Cranmer, Lee⋅Lao, Christopher⋅Lao, Christopher⋅Logan, Theodore⋅Logan, Theodore⋅Lutzky, Jose⋅Lutzky, Jose⋅Rudrapatna, Venkatesh⋅Rudrapatna, Venkatesh⋅Daniels, Gregory⋅Daniels, Gregory⋅Taback, Bret⋅Taback, Bret⋅Aung, Sandra⋅Aung, Sandra⋅Lowder, James⋅Lowder, James⋅Lawson, David and Lawson, David2014.
| Journal Article
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.Ribas, Antoni⋅Gonzalez, Rene⋅Pavlick, Anna⋅Hamid, Omid⋅Gajewski, Thomas F⋅Daud, Adil⋅Flaherty, Lawrence⋅Logan, Theodore⋅Chmielowski, Bartosz⋅Lewis, Karl⋅Kee, Damien⋅Boasberg, Peter⋅Yin, Ming⋅Chan, Iris⋅Musib, Luna⋅Choong, Nicholas⋅Puzanov, Igor and Mc Arthur, Grant AThe Lancet. Oncology, vol. 15, (no. 9), pp. 954-965, August 2014.
| Journal Article
Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinibAmin, Asim⋅Dudek, Arkadiusz Z⋅Logan, Theodore F⋅Lance, Raymond S⋅Holzbeierlein, Jeffrey M⋅Master, Viraj A⋅Pal, Sumanta Kumar⋅Knox, Jennifer J⋅Karsh, Lawrence Ivan⋅Plessinger, Doug⋅Nicolette, Charles A and Figlin, Robert AJournal of Clinical Oncology, vol. 32, (no. 15_suppl), pp. 4524, 2014-05-20.
| Journal Article
NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma—Efficacy and biomarker studyAshraf, Madeeha⋅Ashraf, Madeeha⋅Kirkwood, John M⋅Kirkwood, John M⋅Ernstoff, Marc S⋅Ernstoff, Marc S⋅Tawbi, Hussein Abdul Hassan⋅Tawbi, Hussein Abdul-Hassan⋅Frankel, Paul Henry⋅Frankel, Paul Henry⋅Ruel, Nora⋅Ruel, Nora⋅Kendra, Kari Lynn⋅Kendra, Kari Lynn⋅Olencki, Thomas⋅Olencki, Thomas⋅Khushalani, Nikhil I⋅Khushalani, Nikhil I⋅Logan, Theodore F⋅Logan, Theodore F⋅Margolin, Kim Allyson⋅Margolin, Kim Allyson⋅Chen, Alice P⋅Chen, Alice P⋅Tarhini, Ahmad A and Tarhini, Ahmad AJournal of Clinical Oncology, vol. 32, (no. 15_suppl), pp. TPS9120, 2014-05-20.
| Journal Article
Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trialMotzer, Robert J⋅Rini, Brian I⋅McDermott, David F⋅Redman, Bruce G⋅Kuzel, Timothy⋅Harrison, Michael Roger⋅Vaishampayan, Ulka N⋅Drabkin, Harry A⋅George, Saby⋅Logan, Theodore F⋅Margolin, Kim Allyson⋅Plimack, Elizabeth R⋅Waxman, Ian⋅Lambert, Alexandre and Hammers, Hans JJournal of Clinical Oncology, vol. 32, (no. 15_suppl), pp. 5009, 2014-05-20.
| Journal Article
PET/CT assessment of tumor perfusion in metastatic renal cell carcinoma (RCC) before and during sunitinib: A comparison of 15O-water with 62Cu-ETSLogan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Fletcher, James W⋅Fletcher, James W⋅Fletcher, James W⋅Green, Mark A⋅Green, Mark A⋅Green, Mark A⋅Eitel, Jacob Aaron⋅Eitel, Jacob Aaron⋅Eitel, Jacob Aaron⋅Hutchins, Gary⋅Hutchins, Gary and Hutchins, GaryJournal of Clinical Oncology, vol. 32, (no. 15_suppl), pp. 11110, 2014-05-20.
| Journal Article
Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.Lam, Elaine T⋅Lam, Elaine T⋅Wong, Michael K K⋅Wong, Michael K K⋅Agarwal, Neeraj⋅Agarwal, Neeraj⋅Redman, Bruce G⋅Redman, Bruce G⋅Logan, Theodore⋅Logan, Theodore⋅Gao, Dexiang⋅Gao, Dexiang⋅Flaig, Thomas W⋅Flaig, Thomas W⋅Lewis, Karl⋅Lewis, Karl⋅Poust, Jamie⋅Poust, Jamie⋅Monk, Paul⋅Monk, Paul⋅Jarkowski, Anthony⋅Jarkowski, Anthony⋅Sendilnathan, Arun⋅Sendilnathan, Arun⋅Bolden, Marcus⋅Bolden, Marcus⋅Kuzel, Timothy M⋅Kuzel, Timothy M⋅Olencki, Thomas and Olencki, ThomasJournal of immunotherapy (Hagerstown, Md. : 1997), vol. 37, (no. 7), pp. 360-365, September 2014.
| Journal Article
2013
A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trialSarantopoulos, John⋅Dang, Long H⋅Lauer, Richard C⋅Starodub, Alexander⋅Hauke, Ralph J⋅Galsky, Matt D⋅Bylow, Kathryn A⋅Cowey, Charles Lance⋅Bibby, David C⋅Kremmidiotis, Gabriel⋅Doolin, Elizabeth E⋅Lavranos, Tina C⋅Iglesias, Jose Luis⋅Sonpavde, Guru⋅Logan, Theodore⋅Hahn, Noah M⋅Sweeney, Christopher and Hutson, Thomas EJournal of Clinical Oncology, vol. 31, (no. 15_suppl), pp. 4563, 2013-05-20.
| Journal Article
A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL)Melero, Ignacio⋅Gangadhar, Tara C⋅Kohrt, Holbrook Edwin⋅Segal, Neil Howard⋅Logan, Theodore⋅Urba, Walter John⋅Hodi, F. Stephen⋅Ott, Patrick Alexander⋅Perez-Gracia, Jose Luis⋅Wolchok, Jedd D⋅Shah, Aadhar⋅Kurland, John F⋅Cohen, Lewis J⋅Levy, Ronald⋅Wigginton, Jon M and Goldberg, Stacie MJournal of Clinical Oncology, vol. 31, (no. 15_suppl), pp. TPS3107, 2013-05-20.
| Journal Article
Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.Logan, Theodore FCurrent oncology reports, vol. 15, (no. 2), pp. 83-90, 2013/Apr.
| Journal Article
Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapiesBailey, Alexandra S⋅Cheng, SuChun⋅Kwon, Eugene D⋅Leibovich, Bradley C⋅Signoretti, Sabina⋅Dutcher, Janice P⋅Appleman, Leonard Joseph⋅Sosman, Jeffrey Alan⋅Margolin, Kim Allyson⋅Clark, Joseph⋅Khushalani, Nikhil I⋅Curti, Brendan D⋅Ernstoff, Marc S⋅Pantuck, Allan J⋅Vaishampayan, Ulka N⋅Logan, Theodore⋅McDermott, David F and Atkins, Michael BJournal of Clinical Oncology, vol. 31, (no. 15_suppl), pp. 4521, 2013-05-20.
| Journal Article
Phase I dose escalation study of recombinant interleukin-21 (rIL-21, BMS-982470) in combination with ipilimumab (Ipi) in patients (pts) with advanced or metastatic melanoma (MM)Bhatia, Shailender⋅Curti, Brendan D⋅Gordon, Michael S⋅Chesney, Jason⋅Logan, Theodore⋅Thompson, John A⋅Royer, Nels⋅Bittner, Rachel⋅Fontana, David⋅Grosso, Joseph⋅Clemens, Pamela L⋅Cohen, Lewis J⋅Ahlers, Christoph Matthias⋅Wigginton, Jon M and Hwu, PatrickJournal of Clinical Oncology, vol. 31, (no. 15_suppl), pp. TPS3109, 2013-05-20.
| Journal Article
Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumorsChow, Laura Quan Man⋅Gordon, Michael S⋅Logan, Theodore F⋅Antonia, Scott J⋅Bhatia, Shailender⋅Thompson, John A⋅Brahmer, Julie R⋅Solberg, Gretchen⋅Bittner, Rachel⋅Fontana, David⋅Grosso, Joseph⋅Cohen, Lewis J⋅Ahlers, Christoph Matthias⋅Wigginton, Jon M and Drake, Charles GJournal of Clinical Oncology, vol. 31, (no. 15_suppl), pp. TPS3112, 2013-05-20.
| Journal Article
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.Choueiri, Toni⋅Vaishampayan, Ulka⋅Rosenberg, Jonathan E⋅Logan, Theodore F⋅Harzstark, Andrea L⋅Bukowski, Ronald⋅Rini, Brian I⋅Srinivas, Sandhya⋅Stein, Mark N⋅Adams, Laurel M⋅Ottesen, Lone H⋅Laubscher, Kevin H⋅Sherman, Laurie⋅Mc Dermott, David F⋅Haas, Naomi B⋅Flaherty, Keith⋅Ross, Robert⋅Eisenberg, Peter⋅Meltzer, Paul S⋅Merino Neumann, Maria J⋅Bottaro, Don⋅Linehan, W M and Srinivasan, RamaprasadJournal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 31, (no. 2), pp. 181-6, 2013/Jan/10.
| Journal Article
Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC)Amin, Asim⋅Dudek, Arkadiusz⋅Logan, Theodore⋅Lance, Raymond S⋅Holzbeierlein, Jeffrey M⋅Master, Viraj A⋅Pal, Sumanta Kumar⋅Knox, Jennifer J⋅Karsh, Lawrence Ivan⋅Plessinger, Doug⋅Nicolette, Charles A and Figlin, Robert AJournal of Clinical Oncology, vol. 31, (no. 6_suppl), pp. 357, 2013-02-20.
| Journal Article
Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC)Hutson, Thomas E⋅Dang, Long H⋅Lauer, Richard C⋅Starodub, Alexander⋅Hauke, Ralph J⋅Galsky, Matt D⋅Bylow, Kathryn A⋅Cowey, Charles Lance⋅Bibby, David C⋅Kremmidiotis, Gabriel⋅Doolin, Elizabeth E⋅Lavranos, Tina C⋅Sonpavde, Guru⋅Logan, Theodore⋅Hahn, Noah M⋅Sweeney, Christopher and Sarantopoulos, JohnJournal of Clinical Oncology, vol. 31, (no. 6_suppl), pp. 397, 2013-02-20.
| Journal Article
